BRAF and melanoma: The combination of BRAF plus MEK inhibitors (dabrafenib plus trametinib) is licenced in the adjuvant setting only for patients with resected BRAF V600E or BRAF V600K mutant Stage III melanoma, based on the results of the COMBI-AD trial.